News | April 28, 2023
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
Subscribe To Our Newsletter & Stay Updated
